How to improve the outcome of glioblastoma patients

Professor Bart Neyns MD PhD Head of the Department of Medical Oncology Universitair Ziekenhuis Brussel, Brussels, Belgium






Ziekenhuis

Brussel




Bart.Neyns@UZBrussel.be


Classification of Diffuse Glioma





Integrated diagnoses

WHO Classification of Tumours of the Central Nervous System










IDH1/2


1p/19q testing


THE 2017 EANO GUIDELINELANCET ONCOLOGY 2017;18:E315-E329

Standard Treatment for Diffuse Glioma THE 2017 EANO GUIDELINELANCET ONCOLOGY 2017;18:E315-E329



EORTC 26981/22981-NCIC CE3 Phase III Randomized Trial on RT vs. RT/TMZ + TMZ for GBM





Stupp R et al. N Engl J Med 2005; Taphoorn et al. Lancet Oncology 2005; Stupp R et al Lancet Oncology 2009; Mirimanoff RO et al., JCO 2006

The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE

Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma


James R. Perry, M.D., Normand Laperriere, M.D., Christopher J. O'Callaghan, D.V.M., Alba A. Brandes, M.D., Johan Menten, M.D., Claire Phillips, M.B., B.S., Michael Fay, M.B., Ch.B., Ryo Nishikawa, M.D., J. Gregory Cairncross, M.D., Wilson Roa, M.D., David Osoba, M.D., John P. Rossiter, M.B., B.Ch., Arjun Sahgal, M.D., Hal Hirte, M.D., Florence Laigle-Donadey, M.D., Enrico Franceschi, M.D., Olivier Chinot, M.D., Vassilis Golfinopoulos, M.D., Laura Fariselli, M.D., Antje Wick, M.D., Loic Feuvret, M.D., Michael Back, M.B., B.S., Michael Tills, M.B., B.S., Chad Winch, M.Sc., Brigitta G. Baumert, M.D., Volfgang Wick, M.D., Keyue Ding, Ph.D., and Warren P. Mason, M.D., for the Trial Investigators*


METHODS

We conducted a trial involving patients 65 years of age or older with newly diagnosed glioblastoma. Patients were randomly assigned to receive either radiotherapy alone (40 Gy in 15 fractions) or radiotherapy with concomitant and adjuvant temozolomide.



In elderly patients with glioblastoma, the addition of temozolomide to short-course radiotherapy resulted in longer survival than short-course radiotherapy alone. (Funded by the Canadian Cancer Society Research Institute and others; ClinicalTrials.gov number, NCT00482677.)





N Engl J Med 2017;376:1027-37. DOI: 10.1056/NEJMoa1611977

EORTC


The future of cancer therapy


Second interim and 1st molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q codeletion


M J van den Bent, S Erridge, M A Vogelbaum, AK Nowak, M Sanson, A A Brandes, W Wick, P M Clement, J F Baurain, W Mason, H Wheeler, M Weller, K Aldape, P Wesseling, J M Kros, C M S Tesileanu, V Golfinopoulos, T Gorlia, B G Baumert, P French


on behalf of the EORTC Brain Tumor Group and partners














⁶⁷⁴ Neuro-Oncology

20(5), 674–686, 2018 | doi:10.1093/neuonc/nox208 | Advance Access date 28 October 2017

Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143


Antonio Omuro,^{a.d} Gordana Vlahovic,^a Michael Lim, Solmaz Sahebjam, Joachim Baehring, Timothy Cloughesy, Alfredo Voloschin, Shakti H. Ramkissoon, Keith L. Ligon, Robert Latek,^b Ricardo Zwirtes, Lewis Strauss, Prashni Paliwal, Christopher T. Harbison, David A. Reardon,^c and John H. Sampson,^c

Treatment-Related Adverse Events	NIVO3 (n = 10)		NIVO1+IPI3 (n = 10)		NIVO3+IPI1 (n = 20)	
	Any Grade	Grade 3/4	Any Grade	Grade 3/4	Any Grade	Grade 3/4
Gastrointestinal disorders						
Colitis	0	0	2 (20)	2 (20)	1 (5)	1 (5)
Diarrhea	0	0	2 (20)	2 (20)	1 (5)	1 (5)
Pancreatitis	0	0	1 (10)	1 (10)	0	0
Vomiting	0	0	0	0	1 (5)	0
Investigations						
ALT increased	0	0	2 (20)	2 (20)	1 (5)	1 (5)
AST increased	0	0	1 (10)	1 (10)	1 (5)	1 (5)
Lipase increased	0	0	1 (10)	1 (10)	0	0
Bilirubin increased	0	0	1 (10)	0	0	0
Metabolism and nutrition disorders						
Appetite decreased	0	0	1 (10)	1 (10)	0	0
Diabetic ketoacidosis	0	0	1 (10)	1 (10)	0	0
Hyperglycemia	0	0	1 (10)	1 (10)	0	0
Hypocalcemia	0	0	1 (10)	1 (10)	0	0
Hypomagnesemia	0	0	1 (10)	0	0	0
Endocrine disorders						
Hypothyroidism	1 (10)	0	1 (10)	0	0	0
Autoimmune thyroiditis	0	0	0	0	1 (5)	0
Hyperthyroidism	0	0	1 (10)	0	0	0
General disorders and administration	n-site conditions					
Chest pain	1 (10)	0	0	0	0	0
Hepatobiliary disorders						
Cholecystitis	0	0	1 (10)	1 (10)	0	0
Infections and infestations						
Sepsis	0	0	1 (10)	1 (10)	0	0
Psychiatric disorders						
Confusional state	0	0	1 (10)	1 (10)	0	0
Renal and urinary disorders						
Acute kidney injury	0	0	1 (10)	1 (10)	0	0
Respiratory, thoracic, and mediastina	al disorders					
Pneumonitis	1 (10)	0	0	0	1 (5)	0
Skin and subcutaneous tissue disord	ers					
Dermatitis bullous	0	0	1 (10)	0	0	0

Abbreviations: ALT, alamia aminotransferase, AST, aspartate aminotransferase, NIV03, nivolumab 3 mg/kg, NIV01+PID, nivolumab 1 mg/kg iplimitumab 3 mg/kg, NIV03+PI1, nivolumab 3 mg/kg - iplimitumab 1 mg/kg, TRAE, treatment-related adverse event, TRAE, treatment-related serious adverse event, "Adverse event were reported during treatment and nor 100 days following study drug discontinuation and were evaluated according to the CommonTerminology Criteria for Adverse Events v4.0. Adverse events were sorted based on the Medical Dictionary for Regulatory Activities (MedDMA) groupings.

Response	NIVO3 (n = 9)	NIVO1+IPI3 (n = 10)	NIVO3+IPI1 (n = 20)	
Best overall response, n	(%) <i>*</i>			
Complete response	0	0	0	
Partial response	1 (11)	0	2 (10)	
Stable disease	4 (44)	3 (30)	9 (45)	
≥12 wk	2 (22)	2 (20)	4 (20)	
Progressive disease	4 (44)	7 (70)	9 (45)	
Objective response rate, n (%) ^b	1 (11)	0	2 (10)	
95% CI	0.3-48.2	0-30.8	1.2-31.7	

Aboreviations: INVOS, Involumenta a mgrkg: INVO1+IF15, INvolumaba I mg/kg + jiniiimumaba 3 mg/kg; INVO3+IF11, Involumaba 3 mg/kg + jiniimumaba 1 mg/kg. #Best overall response was assessed in responseevaluable patients per RANO criteria.²⁰ #Rate of confirmed complete and partial responses.







Fig. 3 A patient case depicting immune-mediated effects of therapy is presented. (A) MRI scans from a 67-year-old patient treated with NIVO3 who had suspected disease progression, with an increase in lesion size from 12 mm at baseline (left) to 40 mm at day 73 (right). MRI scans were conducted using the same parameters for each scan. (B) Resected tumor at day 81 stained with hematoxylin and eosin indicating immune-mediated changes in lesion size consistent with large aggregates of immune cells (right) and extensive tumor necrosis (left). Scale bar denotes 100 µm. (C) Immunohistochemistry of resected tumor specimens depicts infiltrating immune cell aggregates, T cells, and macrophages. Scale bar denotes 50 µm. *12-mm temporal lobe lesion; no corticosteroid treatment. ^{b40}-mm temporal lobe lesion; patient methylprednisolone 16 mg/day.


FOCUS | ARTICLES https://doi.org/10.1038/s41591-018-0337-7

medicine

Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma

Timothy F. Cloughesy ^{1,2,318}*, Aaron Y. Mochizuki ^{4,18}, Joey R. Orpilla ⁵, Willy Hugo ⁶, Alexander H. Lee ^{1,5}, Tom B. Davidson^{3,4}, Anthony C. Wang⁵, Benjamin M. Ellingson^{3,7}, Julie A. Rytlewski ⁶, Catherine M. Sanders⁸, Eric S. Kawaguchi⁹, Lin Du⁶, Gang Li^{3,9}, William H. Yong¹⁰, Sarah C. Gaffey¹¹, Adam L. Cohen ¹², Ingo K. Mellinghoff¹³, Eudocia Q. Lee¹¹, David A. Reardon¹¹, Barbara J. O'Brien¹⁴, Nicholas A. Butowski¹⁵, Phioanh L. Nghiemphu¹, Jennifer L. Clarke¹⁵, Isabel C. Arrillaga-Romany¹⁶, Howard Colman¹², Thomas J. Kaley¹³, John F. de Groot¹⁴, Linda M. Liau^{3,5}, Patrick Y. Wen^{11,19} and Robert M. Prins ^{2,2,3,17,19*}





Randomized Phase 3 Study Evaluating the Efficacy and Safety of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: CheckMate 143


David A. Reardon, ^{1,2} Antonio Omuro,^{2,a} Alba A. Brandes,³ Johannes Rieger,^{4,5} Antje Wick,⁶ Juan Manuel Sepulveda,⁷ <u>Surasak</u> Phuphanich,⁸ Paul de Souza,⁹ <u>Manmeet</u> S. Ahluwalia,¹⁰ Michael Lim,¹¹ <u>Gordana</u> Vlahovic,^{12,b} John Sampson^{12,b}

¹Dama-Farber Cancer Institute and Harvard University School of Medicine, Boston, MA; ³Memorial Stoan Kettering Cancer Center, New York, NY; ³AUSL-IRCCS Institute of Neurological Sciences, Bologna, Italy; ⁴Kilinikum der Goethe-Universität, Frankfurt, Germany; ⁴University of Tübingen, Germany; ⁴Neurology Chinic, University of Heidelberg, Mannal Center for Tumor Diseases, Heidelberg, Germany; ⁴Hoversity of Tz De <u>Octuber</u>, Madrid, Spain; ⁸Cedars-Sinai Medical Center Los Angeles, CA; ⁴University of Western Sydney School of Medicine, Liverpool, Australia; ⁴⁶Celevaland Clinic, Cleveland, OH; ¹The Johns Hopkins Hospital, Batimere, MD; ⁴Ouke University Medical Center, Durham, NC

Unite	5th Quadrennial Meeting of the World Federation of Neuro-Oncology Societies
Inderstion of the state Streams Oncodings	May 4-7, 2017; Zurich, Switzerland

Co-first authors
 ▷ Co-senior authors

CheckMate 143 Cohort 2 Study Design



1L, first line; CTCAE; Common Terminology Criteria for Adverse Events; MRI, magnetic resonance imaging; ORR, objective response rate; PFS, progression-free survival; QZW, every 2 weeks; Q6W, every 6 weeks; Q6W, every 8 weeks; RANO, Radiologic Assessment in Neuro-Oncology criteria.

Median OS

Events.

Overall Survival and Progression-Free Survival

Nivolumab vs Bevacizumab in Recurrent GBM

Median PFS

Events.

12-Month PFS Rate

12-Month OS Rate

Response per Investigator Assessment

(RANO)

Nivolumab vs Bevacizumab in Recurrent GBM

	Nivolumab n = 153ª	Bevacizumab n = 156ª	
ORR, n (%) [95% CI]	12 (7.8) [4.1, 13.3]	36 (23.1) [16.7, 30.5]	
BOR, n (%)			
CR	2 (1.3)	4 (2.6)	
PR	10 (6.5)	32 (20.5)	
SD	33 (21.6)	73 (46.8)	
PD	107 (69.9)	26 (16.7)	
Unable to determine	1 (0.7)	21 (13.5)	
Not treated	1 (0.7)	16 (10.3)	
Discontinued early due to toxicity	0	3 (1.9)	
Other	0	2 (1.3)	
Median TTR (range), months	3.0 (1.4–12.0)	1.5 (1.2–6.5)	
Median DOR (range), months	11.1 (0.6–18.7)	5.3 (3.1–24.9)	
PFS rate [95% Cl], %			
6-months	15.7 [10.8, 21.5]	29.6 [22.7, 36.9]	
12-months	10.5 [6.5, 15.5]	17.4 [11.9, 23.7]	

[95% CI], months [95% CI], months [95% CI], months [95% CI], months n n Nivolumab 154 9.8 [8.2, 11.8] 41.8 [34.7, 48.8] Nivolumab 171 1.5 [1.5, 1.6] 10.5 [6.5, 15.5] Bevacizumab 147 10.0 [9.0, 11.8] 42.0 [34.6, 49.3] Bevacizumab 146 3.5 [2.9, 4.6] 17.4 [11.9, 23.7] **Overall Survival Progression-Free Survival** 1.0 10 8.0 Survival 0.9 8.0 **Survival** HR = 1.04 [95%CI: 0.83, 1.30] HR = 1.97 [95%CI: 1.57, 2.48] 0.8 P = 0.76 P < 0.0001 Free 0.7 0.6 Overall **Progression** 0.6 Nivolumab Nivolumab 0.5 Bevacizumab Bevacizumab of Censored Censored 0.4 04 Probability **b** 0.3 0.3 Probability 0.2 0.2 0.1 0.1 0.0 0.0 3 12 15 18 21 24 27 12 15 18 21 24 0 0 9 Months Months No. at Risk No. at Risk Nivolumab 184 168 133 96 77 59 39 24 184 41 27 19 18 12 10 9 0 Nivolumab 7 1 0 Bevacizumab 185 135 99 72 48 37 14 27 0 169 5 0 Bevacizumab 185 88 46 32 19 12 3 1

BOR, best overall response; CR, complete response; DOR, duration of response; PD, progressive disease; PR, partial response; SD, stable disease; TTR, time to response Patients evaluable for response. Bristol-Myers Squibb

Press Release

See All Press Releases Sign up for Email Alerts Press Release RSS

Bristol-Myers Squibb Announces Phase 3 CheckMate -498 Study Did Not Meet Primary Endpoint of Overall Survival with Opdivo (nivolumab) Plus Radiation in Patients with Newly Diagnosed MGMT-Unmethylated Glioblastoma Multiforme

CATEGORY: CORPORATE/FINANCIAL NEWS

THURSDAY, MAY 9, 2019 6:59 AM EDT

PRINCETON, N.J.--(<u>BUSINESS WIRE</u>)--<u>Bristol-Myers Squibb Company</u> (NYSE: BMY) today announced the Phase 3 CheckMate -498 trial evaluating *Opdivo* (nivolumab) plus radiation versus temozolomide plus radiation in patients with newly diagnosed O6methylguanine-DNA methyltransferase (MGMT)-unmethylated glioblastoma multiforme (GBM) did not meet its primary endpoint of overall survival (OS) at final analysis. The safety profile of *Opdivo* was consistent with previously reported studies in solid tumors. The Company will complete a full evaluation of the data from CheckMate -498 and work with investigators on the future presentation and publication of the results.

🛞 Bristol-Myers Squibb

Press Release

See All Press Releases Sign up for Email Alerts Press Release RSS

Bristol-Myers Squibb Provides Update on Phase 3 Opdivo (nivolumab) CheckMate -548 Trial in Patients with Newly Diagnosed MGMT-Methylated Glioblastoma Multiforme

CATEGORY: CORPORATE/FINANCIAL NEWS

THURSDAY, SEPTEMBER 5, 2019 6:59 AM EDT

PRINCETON, N.J.--(<u>BUSINESS WIRE</u>)--<u>Bristol-Myers Squibb Company</u> (NYSE: BMY) today announced that the Phase 3 CheckMate -548 trial evaluating the addition of *Opdivo* (nivolumab) to the current standard of care (temozolomide and radiation therapy) versus the standard of care alone

\$BMY provides update on Phase 3 #GBM trial

😈 Tweet this

did not meet one of its primary endpoints, progression-free survival (PFS), in patients with newly diagnosed glioblastoma multiforme (GBM) that is O6-methylguanine-DNA methyltransferase (MGMT)-methylated. The data monitoring committee recommended that the trial continue as planned to allow the other primary endpoint, overall survival (OS), to mature. The company remains blinded to all study data.



GLIAVAX: A STRATIFIED PHASE II CLINICAL TRIAL OF AVELUMAB AND AXITINIB IN PATIENTS WITH RECURRENT GLIOBLASTOMA

Neyns B¹, Ben Salama L¹, Awada G¹, De Cremer J², Schwarze JK¹, Seynaeve L³, Du Four S⁴, Fischbuch L¹, Vanbinst A⁵, Everaert H⁶, Michotte A^{3,7}, Rogiers A⁸, Theuns P², Duerinck J⁴ 1. Department of Medical Oncology, Universitair Ziekenhuis Brussel; 2. Department of Psychology, Vrije Universiteit Brussel; 3. Department of Neurology, UZ Brussel; 4. Department of Neurosurgery, UZ Brussel; 5. Department of Radiology, UZ Brussel; 6. Department of Nuclear Medicine, UZ Brussel; 7. Department of Pathology, UZ Brussel; 8. Department of Psychiatry, Universitair Verplegingscentrum Brugmann

INTRODUCTION

- Patients (pts) with recurrent glioblastoma (rGB) have a poor prognosis. No treatment has shown to improve survival.
- Axitinib (AXI), an oral VEGFR 1-3 inhibitor, has demonstrated single-agent activity in rGB and reduces the need for corticosteroids (CS) by its anti-edematous action.
- Avelumab (AVE), a programmed cell death ligand 1 (PD-L1) IgG1 blocking antibody, has demonstrated activity in several tumor types. AXI + AVE is approved for the treatment of metastatic renal cell carcinoma.
- The combination of AXI and AVE may improve the outcome of patients with rGB.

METHODS

- Phase 2 open-label, single-center, dual-stratum clinical trial (Universitair Ziekenhuis Brussel)
- Inclusion criteria: - rGB following prior surgery, radiation therapy and temozolomide chemotherapy - Not amenable for surgery
- Stratification according to baseline use of corticosteroids:
 Cohort-1: ≤ daily physiologic dose
 Cohort-2: > daily physiologic dose
- Intervention:
 - Cohort-1: start with AXI 5 mg BID + AVE 10 mg/kg Q2W
 Cohort-2: start with AXI 5 mg BID; addition of AVE 10 mg/kg Q2W after 6 weeks (wks) if CS tapered to ≤ daily physiologic dose
- Treatment until progressive disease (by immunotherapy Response Assessment for Neuro-Oncology [iRANO] criteria), unacceptable toxicity or withdrawal of consent
- Primary endpoint:
- 6-month-progression-free survival rate (6-m-PFS, %)
- Secondary endpoints: - Objective response rate (ORR) - Overall survival (OS) - Safety graded by CTCAE version 4 - Evolution of neurocognitive function
- Sample size: 26 pts according to Fleming one-stage design (prespecified 6-m-PFS of ≥ 50%; alpha 0.10; beta 0.20)
- Drug supply by Pfizer/Merck Serono
- ClinicalTrials.gov Identifier: NCT03291314


Corresponding author: Bart Neyns, MD, PhD - Bart.Neyns@uzbrussel.be




				RESULTS			
TABL	E 1. BASELINE CHARACTERISTICS*			TABLE 3. ADVERSE EVENTS (AE) IN PTS WHO RECEIVED AT LEAST ONE DOSE OF STUDY DRUGS			
	Overall (n=54)	Cohort-1 (n=27)	Cohort-2 (n=27)		DOSE OF STUDY DRU		Co
Gender (n [%])				AE (in 10% or more of pts)	All-grade (n [%])	Grade 3-4 (n [%])	
Male	34 (63.0)	14 (25.9)	20 (37.0)	Dysphonia	36 (66.7)	0 (0)	
Female	20 (37.0)	13 (24.1)	7 (13.0)	Lymphopenia	27 (50.0)	2 (3.7)	
Median age (range)	55 (19-75)	57 (20-70)	47 (19-75)	Hypertension	26 (48.1)	4 (7.4)	
WHO Performance	. ,			Diarrhea	26 (48.1)	2 (3.7)	
Status (n [%])				Fatigue	25 (46.3)	4 (7.4)	
0	27 (50.0)	20 (37.0)	7 (13.0)	Thrombocytopenia	25 (46.3)	1 (1.9)	
1	22 (40.7)	6 (11.1)	16 (29.6)	Erythrocytosis TSH increase	18 (33.3) 16 (29.6)	0 (0)	-
2	. ,		4 (7.4)	ALT increase		1 (1.9)	-
	5 (9.3)	1 (1.9)	4 (7.4)	ALI Increase Mucositis/aphtosis	14 (25.9) 13 (24.1)	1 (1.9) 0 (0)	-
Diagnosis				GGT increase	9 (16.7)	5 (9.3)	
De novo GB	35 (64.8)	18 (33.3)	17 (31.5)	AST increase	9 (16.7)	1 (1.9)	-
Secondary GB	19 (35.2)	9 (16.7)	10 (18.5)	Neutrophilia	9 (16.7)	0 (0)	
*Two extra pts were inc	luded, one in ea	ch cohort.		Anorexia	8 (14.8)	1 (1.9)	-
				Headache	6 (11.1)	0 (0)	
TABLE 2. OBJECT	IVE RESPONSE	AND DISEASE C	ONTROL RATE	Chills-acute infusion reaction	6 (11.1)	0 (0)	· ·
	Overall (n=5			AP increase	6 (11.1)	0 (0)	
0	· · ·	· · · ·	· · · ·	AE OF SPECIAL INTEREST	All-grade (n [%])	Grade 3-4 (n [%])	1
Confirmed ORR (n [%])		9 (33.3)	6 (22.2)	Papulopustular rash	4 (7,4)	0 (0)	•
	CR 2 (3.7)	1 (3.7)	1 (3.7)	Rash NOS	3 (5.6)	0 (0)	
	PR 13 (24.1)	8 (29.6)	5 (18.5)	Pulmonary embolism	3 (5.6)	3 (5.6)	-
	SD 15 (27.8)	8 (29.6)	7 (25.9)	Hepatitis*	2 (3.7)	1 (1.9)	•
F	PD 24 (44.4)	10 (37.0)	14 (51.9)	Seborrheic rash	2 (3.7)	0 (0)	
Disease control rate	30 (55.6)	17 (63.0)	12 (40.4)	Pneumonitis*	1 (1.9)	1 (1.9)	-
(n [%])	30 (55.6)	17 (03.0)	13 (48.1)	Psoriasiform rash	1 (1.9)	1 (1.9)	1
Median duration of				Microscopic colitis	1 (1.9)	0 (0)	1
response (wks)	18.0	17.9	19.0	* One pt with both pneumonitis and hep			1
,							
							4
100	FIGURE 1. PRO	GRESSION-FREE	SURVIVAL	100	FIGURE 2. OVERALL S	URVIVAL	
		Cohort-1	Cohort-2		Cohort-1	Cohort-2	
10	n (wks, 95% Cl) S (%, 95% Cl)	12.0 (8.2-15.8) 22.2 (6.5-37.9)	10.7 (5.3-16.1) 18.5 (3.8-33.2)	″ _ _ M ™ _ _ (wks, 9	Aedian 28.6 (20.8.22.4)		FI
70	0 (70, 00 % 01)	22.2 (0.0-07.0)	10.0 (0.0-00.2)		m-OS % CI) 66.7 (48.9-84.5)	37.0 (18.8-55.2)	

RESULTS

FIGURE 3. SWIMMER PLOTS: TIME ON AXI MONOTHERAPY, PFS and OS Color legenda: light blue: PFS on AXI monotherapy (cohort-2 only); dark blue: PFS on AXI + AVE; orange: OS; black block: death; arrow: pt on treatment.










CONCLUSION

The combination of AXI + AVE is well tolerated but did not meet the threshold for activity justifying further investigation in an unselected population of patients with rGB.

POSTER PRESENTED AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING, 31ST MAY - 4TH JUNE 2019, CHICAGO, IL

Glitipni



Cancer Cell Article

Cancer Cell


Cancer Cell 26, 1–15, November 10, 2014


Dissecting the Tumor Myeloid Compartment Reveals Rare Activating Antigen-Presenting Cells Critical for T Cell Immunity

Miranda L. Broz,¹ Mikhail Binnewies,¹ Bijan Boldajipour,¹ Amanda E. Nelson,¹ Joshua L. Pollack,² David J. Erle,² Andrea Barczak,² Michael D. Rosenblum,³ Adil Daud,⁴ Diane L. Barber,⁵ Sebastian Amigorena,⁷ Laura J. van't Veer,⁶ Anne I. Sperling,⁸ Denise M. Wolf,⁶ and Matthew F. Krummel^{1,*}


Cancer Cell 30, 324–336, August 8, 2016 © 2016

Critical Role for CD103⁺/CD141⁺ Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in Melanoma






- Across multiple mouse tumor models and human tumor biopsies, intratumoral myeloid dendritic cell (DC) populations identified as distinct from macrophage populations
- Within these, CD103+ DCs are extremely sparse and yet remarkably capable CTL stimulators.
- These are uniquely dependent on IRF8, Zbtb46, and Batf3 transcription factors
- Generated by GM-CSF and FTL3L cytokines
- Regressing tumors have higher proportions of these cells
- T-cell-dependent immune clearance relies on them
- Abundance of their transcripts in human tumors correlates with clinical outcome
- This cell type presents opportunities for prognostic and therapeutic approaches across multiple cancer types.



Res; 22(9) May 1, 2016; Jurjen Cancer Res 2013;73:1063-1075

Julia Katharina Schwarze et al, ESMO IO 2018 and SITC AM 2019



The Dendritic Cell Strikes Back

Christino Moussion¹ and Ira Meliman^{1,0} Constituely South San Francisco, California (2000), USA Consequencing (1997), Consequencing (1997) Reserved (1997), Consequencing (19 Optimism is a duty. The future is open. It is not predetermined. No one can predict it, except by chance. We all contribute to determining it by what we do. We are all equally responsible for its success.

Karl Popper

WWW.STOREMYPIC.COM

Acknowledgements

The patients who consented to participate in these clinical trials, their families and caregivers

Johnny Duerinck Julia Katharina Schwarze, Gil Awada Sofie Wilgenhof, Yanina Jansen Katrien van den Bossche, Maud Allard Ivan Van Riet Ines Dufait



